bone; 51 patients had metastatic cancer without overt bony involvement; and 13 patients had local disease without bone metastases. To evaluate the predictive value of these markers in the metastatic population, we utilized a "Z-score" and logistic regression analysis to distinguish patients with documented bone metastatic disease from those patients without clinical evidence of bone metastases. The higher the Z-score, the better the marker predicts the presence of bone metastases. With this statistical approach, urine N-telopeptide measurements had the highest Z-score and the most significant association with the probability of bone metastases. Urine deoxypyridinoline was the second most predictive marker of bone metastases. Thus, biochemical markers of bone resorption might be of use to predict the presence of bone metastases in cancer patients and to monitor the efficacy of antiresorptive therapy in patients treated for metastatic bone disease.
Several biochemical markers of bone formation and bone resorption have recently been developed. These markers have been evaluated for clinical utility in patients with metabolic bone disease, including Paget disease and osteoporosis, and for their potential use in cancer patients whose disease has metastasized to bone. We have evaluated seven markers of bone turnover in the plasma and urine of 94 patients with newly diagnosed or progressive malignancy with and without clinical evidence of bone metastases. As determined by a positive bone scan and (or) bone survey, 30 patients had metastases to bone; 51 patients had metastatic cancer without overt bony involvement; and 13 patients had local disease without bone metastases. To evaluate the predictive value of these markers in the metastatic population, we utilized a "Z-score" and logistic regression analysis to distinguish patients with documented bone metastatic disease from those patients without clinical evidence of bone metastases. The higher the Z-score, the better the marker predicts the presence of bone metastases. With this statistical approach, urine N-telopeptide measurements had the highest Z-score and the most significant association with the probability of bone metastases. Urine deoxypyridinoline was the second most predictive marker of bone metastases. Thus, biochemical markers of bone resorption might be of use to predict the presence of bone metastases in cancer patients and to monitor the efficacy of antiresorptive therapy in patients treated for metastatic bone disease. We measured serum concentrations of the bone formation markers, total and bone-specific alkaline phosphatase (B-AP), and several bone resorption markers, including serum concentrations of the collagen cross-link-associated C-telopeptide (ICTP) and urine concentrations of the pyridinium cross-links pyridinoline (PYD) and deoxypyridinoline (DPD) and the collagen cross-link-associated N-telopeptide (NTX).4 These markers were examined statistically with logistic regression analysis and a calculated "Z-score" to determine which marker or markers were the best predictors of the presence of bone metastases. Lc. The upper reference limit for these assays is indicated by the broken line.
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Patients
Bone Alkaline Phosphatase N-telopeptide respectively). Thus, only NTX and log(NTX) appear to provide any amount of discrimination between the nobone metastases and the bone metastases groups. As expected, log(NTX) was the marker that entered in the first stage of the stepwise multiple logistic regression analysis. However, no other marker provided a significant contribution (P >0.10) in the presence of log(NTX) in the second stage of the stepwise analysis; therefore, the analysis terminated at that point. Fig. 4 represents a comparative Z-score for all the biochemical markers tested in our cancer population. NTX had the highest Z-score of the markers of bone loss evaluated, whereas B-AP had the highest Z-score of the bone formation markers studied. 
Discussion
